PHARMACOTHERAPY FOR UNCOMPLICATED INFLAMMATORY DISEASES OF SMALL PELVIC ORGANS

Objective. To study possibilities of application of combiflox (ornidazol 500 g + ofloxacin 200 mg) to treat uncomplicated small pelvic inflammatory diseases identified by a gynecologist during annual prophylactic examination. Subject and methods. Fifty-four reproductive-aged patients having signs of small pelvic inflammatory small pelvic inflammatory diseases were selected; of them 26 patients had predominant involvement of the vagina and cervix uteri, without the signs of a risk for ascending infection and 28 patients had evidence for inflammation of the uterus or its appendages in the presence of risk of disease complication. All the patients took the combination agent ornidazol + ofloxacin as 2 tablets daily for 7 to 14 days depending on the severity of disease symptoms. The effect was evaluated from clinical, ultrasound, and laboratory data; drug tolerance was assessed using the data of a questionnaire survey in patients and their subjective attitude towards treatment. Results. Among the reproductive-aged patients with signs of uncomplicated small pelvic inflammation, combiflox proved to be effective in 88.5% of cases and among those having risk factors for ascending infection in 75% of the patients. Three of the 54 patients were operated on because of the signs of formed tuboovarian mass and antibiotics were changed in 7 women who had no improvement for 5 days. There were no severe adverse manifestations due to the use of combiflox. All the women reported that the dosage form was easy-to-use. Conclusion. In the authors’ experience, combiflox is an effective agent for women with uncomplicated diseases of small pelvic organs as a combination of ornidazol and ofloxacin affects major microbial pathogens. The convenient formulation of the combined drug and its reasonable price allows high treatment compliance.

small pelvic inflammatory diseases, ornidazol, ofloxacin, bacterial vaginosis, diagnosis, treatment